Thromboembolism and resistance to activated protein C in patients with inflammatory bowel disease

American Journal of Gastroenterology

Volumn 94, Issue 3, 1999, Pages 685-690

  Novacek, Gottfried ^a   Miehsler, Wolfgang ^b   Kapiotis, Stylianos ^b   Katzenschlager, Reinhold ^b   Speiser, Wolfgang ^b   Vogelsang, Harald ^b  

^a UNIVERSITY OF VIENNA   (Austria)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

PROTEIN C;

ADOLESCENT; ADULT; ARTICLE; CROHN DISEASE; ENTERITIS; FEMALE; HUMAN; INTESTINE STENOSIS; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RISK FACTOR; THROMBOEMBOLISM; THROMBOGENESIS; ULCERATIVE COLITIS; VEIN THROMBOSIS;

ACTIVATED PROTEIN C RESISTANCE; ADOLESCENT; ADULT; AGED; ANTITHROMBIN III; C-REACTIVE PROTEIN; FEMALE; FIBRINOGEN; HUMANS; INFLAMMATORY BOWEL DISEASES; MALE; MIDDLE AGED; RISK FACTORS; THROMBOEMBOLISM;

EID: 0032979156     PISSN: 00029270     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0002-9270(98)00818-1     Document Type: Article

References (45)

1. Bargen JA, Barker NW. Extensive arterial and venous thrombosis complicating chronic ulcerative colitis. Arch Intern Med 1936;58:17-31.
2. Sloan WP, Barger JA, Gage RP. Life histories of patients with chronic ulcerative colitis: A review of 2000 cases. Gastroenterology 1950;16:25-38.
3. Graef V, Baggenstors AH, Sauer WG, et al. Venous thrombosis occuring in non-specific ulcerative colitis. A necropsy study. Arch Intern Med 1966;117:377-82.
4. Edwards FC, Truelove SC. The course and prognosis of ulcerative colitis. III. Complications. Gut 1964;5:1-22.
5. Talbot RW, Hepell J, Dozois RR, et al. Vascular complications of inflammatory bowel disease. Mayo Clin Proc 1986; 61:140-5.
6. Jackson LM, O'Gorman PJ, O'Connell J, et al. Thrombosis in inflammatory bowel disease: Clinical setting, procoagulant profile and factor V Leiden. Q J Med 1997;90:183-8.
7. Dahlbäck B, Carlsson M, Svensson PJ. Familial thrombophilia due to a previously unrecognized mechanism characterized by poor anticoagulant response to activated protein C: Prediction of a cofactor to activated protein C. Proc Natl Acad Sci USA 1993;90:1004-8.
8. Koster T, Rosendaal FR, de Ronde H, et al. Venous thrombosis due to poor anticoagulant response to activated protein C: Leiden Thrombophilia Study. Lancet 1993;342:1503-6.
9. Svensson PJ, Dahlbäck B. Resistance to activated protein C as a basis for venous thrombosis. N Engl J Med 1994;330:517-22.
10. Griffin JH, Evatt B, Wideman C, et al. Anticoagulant protein C pathway defective in a majority of thrombophilic patients. Blood 1993;82:1989-93.
11. Bertina RM, Koeleman BPC, Koster T, et al. Mutation in blood coagulation factor V associated with resistance to activated protein C. Nature 1994;369:64-7.
12. Greengard JS, Sun X, Xu X, et al. Activated protein C resistance caused by Arg506Gln mutation in factor Va. Lancet 1994;343:1361-2.
13. Voorberg J, Roelse J, Koopman R, et al. Association of idiopathic thromboembolism with single point mutation at Arg506 of factor V. Lancet 1994;343:1535-6.
14. Zöller B, Dahlbäck B. Linkage between inherited resistance to activated protein C and factor V gene mutation in venous thrombosis. Lancet 1994;343:1536-8.
15. Ridker PM, Hennekens CH, Lindpaintner K, et al. Mutation in the gene coding for coagulation factor V and the risk of myocardial infarction, stroke, and venous thrombosis in apparently healthy men. N Engl J Med 1995;332:912-7.
16. Rees DC, Cox M, Clegg JB. World distribution of factor V Leiden. Lancet 1995;346:1133-4.
17. Ridker PM, Miletich JP, Hennekens CH, et al. Ethnic distribution of factor V Leiden in 4047 men and women. Implication for venous thromboembolism screening. JAMA 1997; 277:1305-7.
18. Rosendaal FR, Koster T, Vandenbroucke JP, et al. High risk of thrombosis in patients homozygous for factor V Leiden (activated protein C resistance). Blood 1995;85:1504-8.
19. Eichinger S, Pabinger I, Stümpflen A, et al. The risk of recurrent venous thromboembolism in patients with and without factor V Leiden. Thromb Haemost 1997;77:624-8.
20. Probert CSJ, Haslam N, Aslam S, et al. Is factor V Leiden associated with inflammatory bowel disease? Gut 1997; 41(Suppl 3):A36.
21. Levine A, Lahav J, Zahavi I, et al. Activated protein C resistance in pediatric inflammatory bowel disease. J Ped Gastroenterol Nutrition 1998;26:172-4.
22. Malchow H, Ewe K, Brandes JW, et al. European cooperative Crohn's disease study (ECCDS): Results of drug treatment. Gastroenterology 1984;86:249-66.
23. Rachmilewitz D. Coated mesalazine (5-aminosalicylic acid) versus sulphasalazine in the treatment of active ulcerative colitis: A randomized trial. BMJ 1989;298:82-6.
24. Best WR, Becktel JM, Singelton JW, et al. Development of a Crohn's disease activity index: National Cooperative Crohn's Disease Study. Gastroenterology 1976;70:439-44.
25. Van Wersch JW, Houben P, Rijken J. Platelet count, platelet function, coagulation activity and fibrinolysis in the acute phase of inflammatory bowel disease. J Clin Chem Clin Biochem 1990;28:513-7.
26. Morowitz DA, Allen LW, Kirsner JB. Thrombocytosis in chronic inflammatory bowel disease. Ann Intern Med 1968; 68:1013-21.
27. Simi M, Leardi S, Tebano MT, et al. Raised plasma concentrations of platelet factor 4 (PF 4) in Crohn's disease. Gut 1987;28:336-8.
28. Webberley MJ, Hart MT, Melikian V. Thromboembolism in inflammatory bowel disease: Role of platelets. Gut 1993;34: 247-51.
29. Collins CE, Cahill MR, Newland AC, et al. Platelets circulate in an activated state in inflammatory bowel disease. Gastroenterology 1994;106:840-5.
30. Edwards RL, Levine JB, Green R, et al. Activation of blood coagulation in Crohn's disease. Increased plasma fibrinopeptid A and enhanced generation of monocyte tissue factor activity. Gastroenterology 1987;92:329-37.
31. De Jong E, Porte RJ, Knot EA, et al. Disturbed fibrinolysis in patients with inflammatory bowel disease. A study in blood plasma, colon mucosa and faeces. Gut 1989;30:188-94.
32. Hudson M, Hutton RA, Wakefield AJ, et al. Evidence for activation of coagulation in Crohn's disease. Blood Coagul Fibrinolysis 1992;3:773-8.
33. Smith CJ, Haire WD, Kaufman SS, et al. Determination of prothrombin activation fragments in young patients with inflammatory bowel disease. Am J Gastroenterol 1996;91: 1221-5.
34. Novacek G, Vogelsang H, Genser D, et al. Changes in blood rheology caused by Crohn's disease. Eur J Gastroenterol Hepatol 1996;8:1089-93.
35. Hudson M, Chitolie A, Hutton RA, et al. Thrombotic vascular risk factors in inflammatory bowel disease. Gut 1996;38:733-7.
36. Kapiotis S, Quehenberger P, Jilma B, et al. Improved characteristics of aPC-resistance assay. Coated aPC resistance by predilution of samples with factor V deficient plasma. Am J Clin Pathol 1996;106:588-93.
37. Aboud MR, Ma DD. A comparison between two activated protein C resistance methods as routine diagnostic tests for factor V Leiden mutation. Br J Haematol 1997;97:798-803.
38. 506 mutation - evaluation of thirteen plasma-based methods for their diagnostic efficacy in comparison with DNA analysis. Thromb Haemost 1996;77:436-9.
39. Gouault-Heilmann M, Leroy-Matheron C. Factor V Leiden-dependent APC resistance: Improved sensitivity and specificity of the APC resistance test by plasma dilution in factor V-depleted plasma. Thromb Res 1996;82:281-3 (letter).
40. Trossaërt M, Conard J, Horellou MH, et al. The modified APC resistance test in the presence of factor V deficient plasma can be used in patients without oral anticoagulant. Thromb Haemost 1996;75:521-2 (letter).
41. Huber W, Jeschke B, Schweigart U, et al. Intensivtherapie chronisch-entzündlicher Darmerkrankungen. Wien Klin Wochenschr 1998;110(suppl 1):26.
42. Wakefield AJ, Sawyerr AM, Dhillon AP, et al. Pathogenesis of Crohn's disease: Multifocal gastrointestinal infarction. Lancet 1989;ii:1057-62.
43. Sankey EA, Dhillon AP, Anthony A, et al. Early mucosal changes in Crohn's disease. Gut 1993;34:375-81.
44. Nick PT, Wakefield AJ, Pounder RE. Inherited disorders of coagulation appear to protect against inflammatory bowel disease. Gastroenterology 1995;108:1011-5.
45. Gaffney PR, Doyle CT, Gaffney A, et al. Paradoxical response to heparin in 10 patients with ulcerative colitis. Am J Gastroenterol 1995;90:220-3.